The TB Europe Coalition (TBEC) is an advocacy network that brings together civil society representatives (individuals and organisations) from across the WHO European Region; in order to strengthen the role of civil society within the region response to tuberculosis (TB), and to increase the political and financial commitment required to effectively control the epidemic in the region.
The year 2017 is the 3rd year of the FPA and another critical year for the fight against tuberculosis (TB) in Europe. The latest evidence continues to affirm that the fight against TB, and particularly drug-resistant TB, is far from won in the region and sustained community advocacy, capacity building, and high-level advocacy are needed to achieve this goal.

Main specific objectives of the programme:
1) Increase understanding of the civil society contribution to TB response across 80% of the Region by the end of 2017;
2) By the end of 2017, maintain and strengthen the TBEC website as a regional platform serving 400 civil society stakeholders working within the TB response;
3) Provide access to TBEC support and representation to civil society stakeholders in at least 80% of countries within the Region by the end of 2017;
4) Strengthen the voice of civil society in all accessible EU, regional and international forums/consultations throughout 2017;
5) Manage TBEC’s governance and internal processes for the successful implementation of this work programme throughout 2017.

These objectives will be achieved via the delivery of key outputs:
- Mapping civil society stakeholders across the region;
- Facilitate access to information and resources for target groups;
- Conduct outreach to civil society across the region with the aim of expanding the network and building relationships with target groups;
- Engage with decision-makers to advocate on behalf of civil society across the region;
- Manage the network effectively to implement the three-year work programme.



Every action the European Heart Network (EHN) undertakes aims to achieve its mission: to prevent and reduce cardiovascular disease (CVD).

To establish its operational objectives and construct its work programme for 2018, EHN has scanned the EU policy horizon and consulted widely with its members.

EU policy areas upon which we will act include sustainable development, common agriculture policy and trade. We aim to inject consideration of CVD/chronic diseases into these areas to help achieve SDG goal 3.4 and the WHA 25x25 targets.

A major focus in 2018 is implementation of EHN’s policy recommendations contained in its paper “Transforming European food and drink policies for cardiovascular health”.

EHN is a closely-knit member organisation and has, consequently, planned a series of workshops and seminars to strengthen its members' capacities and provide knowledge-exchange opportunities for them. EHN will also strengthen its own operations and continue to ensure good governance.

EHN’s near-to-final 2019-2023 strategy encompasses three pillars (general objectives): I-prevent avoidable CVD; II-strengthen the support for people with CVD; III-reinforce CVD research. These pillars are supported by horizontal objectives and our 2018 work programme includes, notably, an operational objective to ensure a framework of strong cooperation with institutional as well as non-governmental, like-minded organisations working to promote health and reduce risk factors.

In conclusion, we believe that the 10 operational objectives and activities that we have selected for 2018 will contribute to achieve the general and specific objectives set out in our Framework Programme Application of June 2017. We believe that, collectively and albeit in the longer term, they will help address the large inequalities due to CVD in the EU and thus provide substantial EU added value.



The Correlation Network (CN) is a European civil society network and centre of expertise in the field of drug use, harm reduction and social inclusion.

Overall objective of this proposal:
Improve the access to and the quality of harm reduction services for People Who Use Drugs (PWUD), including other related vulnerable and marginalised people and to enhance policies and practices that increase social inclusion.

This is achieved by the following strategic objectives
- Strengthen the network and the collaboration with its members and partners through an adequate and solid organisational network structure
- Monitor developments and collect information and evidence in the field of drug use and harm reduction, by involving the expertise of civil society organisations
- Strengthen capacities of the various players in the field of drug use and harm reduction and facilitate exchange between network members and partners
- Advocate for full coverage of harm reduction programmes in Europe, addressing both health and social aspects.

All CN activities will pay specific attention to Hepatitis C, new drug trends and drug patterns and overdose prevention.

Relevant CN outputs include : Sustainable network, Annual Monitoring Reports, Online knowledge and training hub, European Harm Reduction Conferences (2018/20), policy recommendations.

CN contributes to the Third Health Programme (THP) by promoting health (in particular harm reduction), prevent diseases (in particular drug-related diseases and infectious diseases such as HCV and HIV/AIDS), and foster supportive environments for healthy lifestyles (e.g. by reducing barriers to access health and social services).

CN contributes as well to the following THP priorities:
1.2. Drugs-related health damage, including information and prevention
1.3. HIV/AIDS, tuberculosis and hepatitis
2.2. Capacity-building against health threats in Member States, including, where appropriate, cooperation with neighbouring countries.


Under its leading title of the FPA 2018 - 2021, Stronger Together, AIDS Action Europe (AAE) will implement its work programme in 2018. As a comprehensive NGO network of 415 NGOs, national networks, AIDS service organisations, and community based groups in 47 countries in the WHO European Region, AAE is a unique player with substantial added value for European policy making and programme implementation in the response to HIV/AIDS, TB and hepatitis.
Considering the epidemiological background of the three diseases and after consulting AAE Members and partners, the following six core thematic areas were identified to focus on in the upcoming four years:
Community based voluntary counselling and testing (CBVCT)
Affordability and accessibility to medicines
Tackling legal barriers in the response to HIV, TB and hepatitis
Criminalisation of HIV non-disclosure, exposure and transmission
Sexual and reproductive health and rights (SRHR)
Tackling stigma and discrimination
The three main objectives of the work are
1.AAE contributes effectively to the HIV, TB and hepatitis response in Europe
2.AAE provides platforms to communicate and facilitate collaboration, networking, and linking and learning
3.Continuous improvement of network collaboration through governance and internal management.
Within Objective I, AAE will serve as the secretariat to the EU CSF, monitor and contribute to policy developments, coordinate the European HIV Legal Forum, and advocate for CS concerns. Objective 2 comprises improved bilingual communication and exchange, intensified social media communication, dissemination of 3rd health programme information and tools, support of national and regional affordability advocacy efforts and provision of capacity building activities. Eventually, objective III includes ensuring topic-related sub-network cooperation, overall governance by the AAE Steering Committee and implementation, monitoring, evaluation, follow-up and fundraising for the work programme.


TB Europe Coalition (TBEC) is the only regional civil society network working exclusively on TB in the WHO Europe region and, with 171 members in 35 WHO Europe countries, is uniquely positioned to increase the political will needed to end the TB epidemic across the region by strengthening the coordinated response of civil society.
According to the latest figures released by the WHO in the Global Tuberculosis Report 2017, TB continues to be the world’s leading infectious killer, resulting in 10.4 million new infections globally - 600, 000 of which were drug resistant. Unfortunately, the WHO Europe region continues to lead in two key areas of concern - drug resistant TB and TB/HIV co-infection. Nevertheless, TB has maintained a low profile on the regional - and global - political agenda, failing to receive the attention and resources it deserves. 2018 provides unprecedented political opportunities to advance the fight against the epidemic, such as the first ever UN High Level Meeting on Tuberculosis, which could trigger a dramatic shift in the global and European response. A strong, engaged and coordinated civil society will be key to guarantee these opportunities are not missed.
TBEC has identified health system financing, people-centred TB policy, and TB R&D as the key thematic priorities in the region for the next three years.
TBEC has identified four key objectives for 2018 work plan: 1) well-structured TBEC governance and accountability mechanisms; 2) robust processes for communication and external outreach, including one-to-one engagement; 3) strong partnerships with key decision makers, influencers and civil society in interdependent policy areas, in particular TBEC priority thematic areas; and 4) identification of skill gaps and knowledge needs amongst TBEC members, specifically with focus on best practices, as well as opportunities for training programme in 2019.

